Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial

Journal of Infectious Diseases

Volumn 219, Issue 7, 2019, Pages 1026-1034

  Finberg, Robert W ^a   Lanno, Riin ^d   Anderson, David ^c   Fleischhackl, Roman ^e   Van Duijnhoven, Wilbert ^f   Kauffman, Robert S ^b   Kosoglou, Teddy ^c   Vingerhoets, Johan ^g   Leopold, Lorant ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d Merelahe Family Doctors Center   (Estonia)

^e Janssen Cilag Pharma GmbH   (Austria)

^f J J Innovative Medicine   (Belgium)

^g JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Antiviral; Influenza A; Oseltamivir; Pimodivir; Seasonal influenza

Indexed keywords

CREATINE KINASE; OSELTAMIVIR; PIMODIVIR; PLACEBO; ANTIVIRUS AGENT; PB2 PROTEIN, INFLUENZA VIRUS; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; VIRAL PROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFLUENZA A; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEASONAL INFLUENZA; SIDE EFFECT; VIRUS LOAD; VOMITING; ACUTE DISEASE; ANTIVIRAL RESISTANCE; BLOOD; CLINICAL TRIAL; EARLY TERMINATION OF CLINICAL TRIAL; GENETICS; INFLUENZA; INFLUENZA A VIRUS; MIDDLE AGED; PHYSIOLOGY; TIME FACTOR; VIROLOGY; VIRUS SHEDDING;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; DIARRHEA; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; PYRIDINES; PYRIMIDINES; PYRROLES; TIME FACTORS; VIRAL LOAD; VIRAL PROTEINS; VIRUS SHEDDING;

EID: 85063008890     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiy547     Document Type: Article

References (13)

1. Rerksuppaphol S, Rerksuppaphol L. Randomized study of ondansetron versus domperidone in the treatment of children with acute gastroenteritis. J Clin Med Res 2013; 5:460-6.
2. Król E, Rychłowska M, Szewczyk B. Antivirals-current trends in fighting influenza. Acta Biochim Pol 2014; 61:495-504.
3. Miller M, Viboud C, Simonsen L, Olson DR, Russell C. Mortality and morbidity burden associated with A/H1N1pdm influenza virus: who is likely to be infected, experience clinical symptoms, or die from the H1N1pdm 2009 pandemic virus? PLoS Curr 2009; 1:Rrn1013.
4. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM; Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-24.
5. Fu Y, Gaelings L, Söderholm S, et al. JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses. Antiviral Res 2016; 133:23-31.
6. Smee DF, Barnard DL, Jones SM. Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice. Antiviral Res 2016; 136:45-50.
7. Byrn RA, Jones SM, Bennett HB, et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother 2015; 59:1569-82.
8. Trevejo JM, Asmal M, Vingerhoets J, et al. Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study. Antivir Ther 2017.
9. Splinter D, Tanenbaum ME, Lindqvist A, et al. Bicaudal D2, dynein, and kinesin-1 associate with nuclear pore complexes and regulate centrosome and nuclear positioning during mitotic entry. PLoS Biol 2010; 8:e1000350.
10. Clark MP, Ledeboer MW, Davies I, et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem 2014; 57:6668-78.
11. Osborne RH, Norquist JM, Elsworth GR, et al. Development and validation of the influenza intensity and impact questionnaire (FluiiQ"). Value Health 2011; 14:687-99.
12. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355:1845-50.
13. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016-24.